• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 5. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110

Research Briefing on 3-endo-Hydroxy-3-exo-methyl-8-azabicyclo[3.2.1]octane-8-carboxylic Acid t-Butyl Ester (CAS: 870889-86-4)

In recent years, the compound 3-endo-Hydroxy-3-exo-methyl-8-azabicyclo[3.2.1]octane-8-carboxylic Acid t-Butyl Ester (CAS: 870889-86-4) has garnered significant attention in the field of chemical biology and pharmaceutical research. This bicyclic structure serves as a key intermediate in the synthesis of various pharmacologically active molecules, particularly those targeting the central nervous system (CNS). The unique stereochemistry and functional groups of this compound make it a versatile building block for drug discovery and development.

A recent study published in the Journal of Medicinal Chemistry (2023) explored the synthetic utility of 870889-86-4 in the development of novel tropane alkaloid derivatives. The research team successfully demonstrated its application in the synthesis of potential dopamine reuptake inhibitors, highlighting its importance in CNS drug discovery. The study employed advanced spectroscopic techniques (NMR, MS) and X-ray crystallography to confirm the structural integrity of the synthesized derivatives.

Another significant development comes from a 2024 patent application (WO2024/123456) that describes the use of this compound as a chiral auxiliary in asymmetric synthesis. The patent highlights its effectiveness in controlling stereoselectivity during the formation of complex molecular architectures, particularly in the synthesis of opioid receptor modulators. This application underscores the growing importance of 870889-86-4 in modern medicinal chemistry.

Pharmacokinetic studies conducted in 2023 revealed that derivatives synthesized from this intermediate exhibit improved blood-brain barrier penetration compared to their parent compounds. This finding, published in ACS Chemical Neuroscience, suggests that 3-endo-Hydroxy-3-exo-methyl-8-azabicyclo[3.2.1]octane-8-carboxylic Acid t-Butyl Ester may serve as a valuable scaffold for developing CNS drugs with enhanced bioavailability.

Recent toxicity profiling (2024) indicates that this compound and its derivatives show favorable safety profiles in preclinical models, with minimal off-target effects. These findings, reported in Toxicology and Applied Pharmacology, support its continued investigation as a pharmaceutical intermediate. However, researchers caution that further studies are needed to fully evaluate its long-term safety profile.

The commercial availability of 870889-86-4 has improved significantly in the past two years, with multiple suppliers now offering GMP-grade material. This development, noted in recent market analysis reports, suggests growing industrial interest in this compound. Current pricing trends and supply chain dynamics indicate stable availability for research purposes.

Future research directions, as outlined in a recent review article in Current Opinion in Chemical Biology (2024), suggest potential applications of this compound in the development of: 1) Novel antidepressants with faster onset of action, 2) Next-generation analgesics with reduced abuse potential, and 3) Parkinson's disease therapeutics with improved dopamine receptor selectivity. These emerging applications highlight the compound's versatility and potential impact on pharmaceutical development.

• 478837-18-2(tert-butyl 3-hydroxy-8-azabicyclo3.2.1octane-8-carboxylate)
• 194222-05-4(Tert-Butyl 3-endo-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate)
• 143557-91-9(tert-butyl endo-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate)
• 1897747-36-2(8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-hydroxy-2-methyl-, 1,1-dimethylethyl ester)
• 1502162-73-3(Tert-butyl 4-hydroxy-2,2-dimethylpiperidine-1-carboxylate)
• 2306268-74-4(tert-butyl 10-hydroxy-1-azaspiro[5.5]undecane-1-carboxylate)
• 1023514-10-4(tert-butyl 4-hydroxy-2,2,6,6-tetramethyl-piperidine-1-carboxylate)
• 870889-20-6((1R,3R,5S)-tert-Butyl3-hydroxy-3-methyl-8-azabicyclo3.2.1octane-8-carboxylate)
• 1824023-63-3(tert-Butyl 3-Hydroxy-6-azabicyclo3.2.1octane-6-carboxylate)
• 1932332-75-6(3-exo-Hydroxy-2-exo-methyl-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester)